Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12

Intravesical bacillus Calmette-Guerin (BCG) has been used successfully to treat superficial bladder cancer for 3 decades. However, 20–30% of patients will fail initial BCG therapy and 30–50% of patients will develop recurrent tumors within 5 years. Alternative or complementary strategies for the man...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zaharoff, David A., Hoffman, Benjamin S., Hooper, H. Brooks, Benjamin, Compton J., Khurana, Kiranpreet K., Hance, Kenneth W., Rogers, Connie J., Pinto, Peter A., Schlom, Jeffrey, Greiner, John W.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788203/
https://ncbi.nlm.nih.gov/pubmed/19638573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-1114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars